Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know

Abbott Laboratories' stock experienced downward pressure today, primarily driven by a revised full-year earnings outlook. The company lowered its adjusted diluted earnings per share guidance for 2026, indicating an impact from its recent acquisition of cancer diagnostics firm Exact Sciences. While this acquisition is intended to strengthen Abbott's market position in oncology diagnostics, it is expected to result in a near-term earnings dilution.

The company also reported its first-quarter 2026 financial results, which presented a mixed picture. Revenue for the quarter surpassed analyst forecasts. However, adjusted diluted earnings per share met consensus estimates but slightly missed some predictions. Furthermore, certain segments, such as Nutrition, continued to show underperformance, and the Rapid and Molecular Diagnostics division experienced a decline in sales due to a less severe respiratory virus season compared to the prior year.

Adding to investor caution are ongoing legal and operational risks. Recent jury verdicts have ordered Abbott to pay significant damages in lawsuits alleging that its infant formula caused necrotizing enterocolitis. With numerous similar lawsuits pending, this situation raises concerns about potential future financial liabilities and impacts the company's brand perception, particularly within its Nutrition segment.

Analysts have also reacted to these developments, with some firms adjusting their price targets downwards, contributing to a cautious sentiment among investors, despite the overall consensus rating for the stock remaining largely positive.

Technically, Abbott Laboratories (ABT) shows a MACD (12,26,9) value of [-2.41], indicating a neutral signal. The RSI at 37.33 suggests neutral condition and the Williams %R at -63.78 suggests oversold condition. Please monitor closely.

Abbott Laboratories (ABT) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $44.33B, ranking 3 in the industry. The net profit is $6.52B, ranking 2 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $132.05, a high of $158.00, and a low of $113.00.

Company Specific Risks:

• A Chicago jury recently awarded a total of $70 million, including $17 million in punitive damages, against Abbott Laboratories in infant formula lawsuits alleging its product caused necrotizing enterocolitis (NEC) in premature infants, with over 1,700 similar cases pending nationwide.
• The ongoing high-profile legal verdicts related to infant formula have the potential to severely damage Abbott's brand reputation, particularly within its nutrition division, possibly leading to decreased consumer confidence and market share.
• Abbott reported a significant nearly 19% decline in GAAP net earnings and diluted EPS for Q1 2026, primarily attributed to higher operating costs and charges related to its recent acquisition.
• The company's full-year 2026 adjusted diluted EPS guidance includes a projected $0.20 dilution from the Exact Sciences acquisition, indicating an immediate financial drag from integration efforts.